SAM
TCRX icon

Simplify Asset Management’s TScan Therapeutics TCRX Stock Holding History

Simplify Asset Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-904,972
Closed -$1.65M – 159
2025
Q3 		$1.65M Sell
904,972
-141,944
-14% -$251K 0.03% 59
2025
Q2 		$1.52M Hold
1,046,916
– – 0.08% 48
2025
Q1 		$1.44M Hold
1,046,916
– – 0.05% 58
2024
Q4 		$3.18M Hold
1,046,916
– – 0.16% 41
2024
Q3 		$5.21M Hold
1,046,916
– – 0.24% 34
2024
Q2 		$6.12M Hold
1,046,916
– – 0.41% 26
2024
Q1 		$8.31M Hold
1,046,916
– – 0.49% 16
2023
Q4 		$6.1M Hold
1,046,916
– – 0.55% 16
2023
Q3 		$2.68M Hold
1,046,916
– – 0.31% 34
2023
Q2 		$2.62M Buy
1,046,916
+500,000
+91% +$1.34M 0.34% 41
2023
Q1 		$1.15M Buy
+546,916
New +$1.3M 0.16% 58

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Simplify Asset Management's TCRX Position: Q4 2025 in Review

Simplify Asset Management sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 904,972 shares — an estimated $1.65M sold.

Simplify Asset Management first reported a position in TCRX in Q1 2023 and held it in 11 quarters. The position peaked at $8.31M in Q1 2024. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Simplify Asset Management reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplify Asset Management sold 904,972 TScan Therapeutics shares in Q4 2025, an estimated $1.65M.
  • Simplify Asset Management first reported a position in TScan Therapeutics in Q1 2023 and held it in 11 quarters.
  • Simplify Asset Management's TScan Therapeutics position peaked at $8.31M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Simplify Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.